June 2003
Worldwide Biotech;Jun2003, Vol. 15 Issue 6, p8
Trade Publication
Reports on a study conducted by AusAm Biotechnologies Inc. and the National Institutes of Health in Bethesda, Maryland on the lead antiviral drug candidate, DES6, which inhibits the replication and spread of vaccinia virus in tissue culture.


Related Articles

  • A looking-glass war on viruses. Eastwood, Gary // New Scientist;9/14/96, Vol. 151 Issue 2047, p20 

    Reports that German chemists have improved a class of drugs that could sabotage viruses or cancer cells by forming mirror images of the building blocks of nature. Drugs based on chains of nucleotides; Creation of mirror-image copies of RNA-based oligonucleotides; Use of arginine as template.

  • Antiviral drug resistance. Pillay, Deenan; Zambon, Maria // BMJ: British Medical Journal (International Edition);09/05/98, Vol. 317 Issue 7159, p660 

    Presents information on the development of effective antiviral drugs. Biological basis of antibiotic resistance; Measure of drug resistance through specialized laboratories; Information on the drugs used to treat herpes and influenza. INSET: Summary points.

  • Oseltamivir-resistant 2009 H1 N1 increased among immunocompromised patients.  // Infectious Disease News;Sep2011, Vol. 24 Issue 9, p25 

    The article offers a perspective on a research study which indicated the increased emergence of oseltamivir-resistant 2009 H1N1 in England and Scotland, particularly among immunocompromised patients.

  • DMP 266 and indinavir combination.  // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p287 

    Focuses on the study conducted by DuPont Merck's DMP 266 and Crixivan (indinavir), focusing on antiviral drugs. Methodology used in the study; Participants in the study; Circumstances surrounding the study; Conclusions reached.

  • NDA submitted for new formulation of saquinavir.  // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p288 

    Reports on the submission made by Hoffmann-La Roche Incorporated for a formulation of the drug saquinavir mesylate as it relates to antiviral agents. Description of the formulation required; Benefits of using the drug; Information suggesting that marketing clearance be requested for soft...

  • Anti-HIV effects of nelfinavir reported after ten months of combination therapy.  // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p289 

    Reports on the results from a clinical trial conducted on nelfinavir taken with a combination of AZT and 3TC as it relates to antiviral agents. Methodology used in the clinical analysis; Conclusions reached.

  • Human testing of oral PMPA for treatment of HIV begins.  // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p290 

    Evaluates the performance of a oral prodrug of PMPA (oral PMPA) for the potential treatment of Human Indificiency Disease (HIV) infection, focusing on antiviral agents. Methodology used in the evaluation; Definition of PMPA; Circumstances surrounding the evaluation; Conclusions reached.

  • Clinical trial results of GEM...91 show activity against advanced HIV.  // AIDS Patient Care & STDs;Aug97, Vol. 11 Issue 4, p290 

    Reports from Hybridon Incorporated on the results of a clinical trial carried out on the drug GEM... to determine its effectiveness in Human Indificiency Virus (HIV) treatment, focusing on antiviral agents. Methodology used in the clinical analyses; Participants in the trial; Conclusions reached.

  • EFAVIRENZ COMBINATION POTENT AFTER 48 WEEKS.  // AIDS Patient Care & STDs;Feb1998, Vol. 12 Issue 2, p145 

    Reports that according to a study, the combination of the antiviral drug, efavirenz (Sustiva) and indinavir (Crixivan) can be potent after 48 weeks. Number of participants in the study; Reported side effects of patients who took efavirenz.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics